TriangleNCT03762018 · OUTCOME
Progression-free Survival (PFS) According to the mRECIST v1.1
Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.
- Measure
- MEDIAN
- Unit
- months
- Interval / dispersion
- 95% Confidence Interval
- Time frame
- From randomization until documented progression (PD) according to mRECIST v1.1 or death from any cause (whichever occurred first), up to 52 months.
What was measured
PFS is defined as the time from the date of randomisation until documented progression (according to the mRECIST v1.1) or death, if progression is not documented. Censoring (for participants without a PFS/death event) will occur at the date of last tumour assessment. Patients without a post-baseline tumour assessment will be censored at the date of randomization (plus 1 day).
Analysis population: Efficacy population (Intention-To-Treat cohort of all randomised patients)
Groups in this outcome
Atezolizumab Plus Bevacizumab Plus Chemotherapy
Atezolizumab 1200mg intravenously on day 1 every 3 weeks plus bevacizumab 15mg/kg intravenously on day 1 every 3 weeks plus 4-6 cycles of carboplatin AUC 5 plus pemetrexed 500mg/m\^2 intravenously on day 1 every 3 weeks
Bevacizumab Plus Chemotherapy
Bevacizumab 15mg/kg intravenously on day 1 every 3 weeks plus 4-6 cycles of carboplatin AUC 5 plus pemetrexed 500mg/m\^2 intravenously on day 1 every 3 weeks
| Group | Source count |
|---|---|
| Atezolizumab Plus Bevacizumab Plus Chemotherapy | 200 |
| Bevacizumab Plus Chemotherapy | 200 |
Reported measurements
Source class 1
| Group | Value | Spread | Lower | Upper | Comment |
|---|---|---|---|---|---|
| Atezolizumab Plus Bevacizumab Plus Chemotherapy | 9.2 | Not reported | 8.1 | 10.9 | Not reported |
| Bevacizumab Plus Chemotherapy | 7.6 | Not reported | 6.9 | 8.3 | Not reported |
Complete source fields
- classes
- categories
- measurements
- group Id
- OG000
- lower Limit
- 8.1
- upper Limit
- 10.9
- value
- 9.2
- group Id
- OG001
- lower Limit
- 6.9
- upper Limit
- 8.3
- value
- 7.6
- denoms
- counts
- group Id
- OG000
- value
- 200
- group Id
- OG001
- value
- 200
- units
- Participants
- description
- PFS is defined as the time from the date of randomisation until documented progression (according to the mRECIST v1.1) or death, if progression is not documented. Censoring (for participants without a PFS/death event) will occur at the date of last tumour assessment. Patients without a post-baseline tumour assessment will be censored at the date of randomization (plus 1 day).
- dispersion Type
- 95% Confidence Interval
- groups
- description
- Atezolizumab 1200mg intravenously on day 1 every 3 weeks plus bevacizumab 15mg/kg intravenously on day 1 every 3 weeks plus 4-6 cycles of carboplatin AUC 5 plus pemetrexed 500mg/m\^2 intravenously on day 1 every 3 weeks
- id
- OG000
- title
- Atezolizumab Plus Bevacizumab Plus Chemotherapy
- description
- Bevacizumab 15mg/kg intravenously on day 1 every 3 weeks plus 4-6 cycles of carboplatin AUC 5 plus pemetrexed 500mg/m\^2 intravenously on day 1 every 3 weeks
- id
- OG001
- title
- Bevacizumab Plus Chemotherapy
- param Type
- MEDIAN
- population Description
- Efficacy population (Intention-To-Treat cohort of all randomised patients)
- reporting Status
- POSTED
- time Frame
- From randomization until documented progression (PD) according to mRECIST v1.1 or death from any cause (whichever occurred first), up to 52 months.
- title
- Progression-free Survival (PFS) According to the mRECIST v1.1
- type
- SECONDARY
- unit Of Measure
- months
Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f
Preserved source evidence · Not medical advice